Isabel Preeshagul, DO, MBS
Thoracic Oncologist
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist who specializes in caring for people with lung cancer. As an active member of the Thoracic Disease Management Team, I collaborate with specialties including radiation oncology, thoracic surgery, pathology, and interventional radiology. Together, we ensure that we provide extraordinary individualized care. My colleagues and I are committed to addressing not only each person’s disease, but also their unique social circumstances, priorities, and beliefs.
I am particularly interested in using precision medicine when planning treatment. This personalized approach allows us to provide the highest quality of care all closer to home at MSK Bergen, where I practice.
Read more
At all of MSK’s locations, people with lung cancer have a variety of treatment options and, if eligible, can participate in cutting-edge clinical trials. These studies take many forms, but all are directed toward learning more about their disease. MSK is leading the way in using precision medicine to select the most appropriate therapy based on the characteristics of your cancer. One size does not fit all and we take pride in offering each of our patients a comprehensive treatment plan designed just for them.
My research focuses on personalized medicine and using biomarkers to predict a person’s response to a treatment. By identifying these unique targets, we can select treatments that may be more effective. Knowing what the best treatment is for a particular person can minimize their exposure to toxicity from therapies that may be less beneficial to them. I have presented this work both nationally and internationally and continue to collaborate with my colleagues from multiple disciplines to advance this growing field.
I aim to ensure that my patients are an integral part of their treatment team. My goal is for them to feel supported and in control. I will continue my joint research efforts to provide better outcomes and improved quality of life for our patients.
My Specialties
- Lung Cancer
Education
- DO, Lake Erie College of Osteopathic Medicine
- MBS, Rutgers University School of Biomedical Sciences
Residencies
- Internal Medicine – Icahn School of Medicine at Mount Sinai-Mount Sinai Beth Israel
Awards and Honors
- Chair, Patient Education and Engagement Committee for the Lung Cancer Research Foundation (2022-present)
- Host, “Together Separately” webinar, Lung Cancer Research Foundation (2022-present)
- Keynote Speaker at Relay for Life-FLOW (2018)
- Peer-Nominated Patient Care Award, North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health (2018)
- Chief Hematology Oncology Fellow (2017-2018)
Fellowships
- Hematology/Oncology – North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Preeshagul sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Preeshagul
- A Phase II Study of Durvalumab Immunotherapy and Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. PMID: 34022698.
Thor M, Shepherd AF, Preeshagul I, Offin M, Gelblum DY, Wu AJ, Apte A, Simone CB 2nd, Hellmann MD, Rimner A, Chaft JE, Gomez DR, Deasy JO, Shaverdian N. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. Radiother Oncol. 2022 Feb;167:158-164. doi: 10.1016/j.radonc.2021.12.016. Epub 2021 Dec 20. PMID: 34942280; PMCID: PMC9518843.
Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.
Read more
Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.
Seetharamu N, Preeshagul I, Sullivan K. New PDL-1 Inhibitors In NSCLC - Impact of Atezolizumab. Lung Cancer Targets and Therapy. 2017 July;13 (8): 67-78.
Sullivan K, Preeshagul I, Budman D, Seetharamu N. Immune checkpoint inhibitors in lung cancer: an update. Future Oncol. 2017 May;13(11):955-959. doi: 10.2217/fon-2017-0044. PMID: 28481150.
Saxena A, Becker D, Preeshagul I, Lee K, Katz E, Levy B. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Oncologist. 2015 Aug;20(8):934-45. doi: 10.1634/theoncologist.2015-0064. Epub 2015 Jul 8. PMID: 26156329; PMCID: PMC4524771.
Visit PubMed for a full listing of Dr. Preeshagul’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Isabel Preeshagul discloses the following relationships and financial interests:
-
Aptitude Health
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Boehringer Ingelheim
Professional Services and Activities (Uncompensated) -
Dava Oncology
Professional Services and Activities -
G1 Therapeutics
Professional Services and Activities -
Genentech
Professional Services and Activities
-
Jazz Pharmaceuticals
Professional Services and Activities -
LabCorp
Professional Services and Activities -
Novartis
Professional Services and Activities -
Pfizer, Inc.
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
